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Abstract: 
Alkylamides present in Echinacea species have reported immunomodulatory actions, yet their 
direct effects on T lymphocytes, key mediators of antiviral immunity, are poorly understood. We 
hypothesized that constituents present in ethanolic extracts of Echinacea species exert direct 
immunomodulatory effects on human Jurkat T cells. Modulation of IL-2 production by 
submaximally stimulated Jurkat cells was determined in response to treatment with extracts 
prepared from dried aerial parts of Echinacea purpurea. Cells were treated with the extracts, 
with alkylamides or caffeic acid derivatives isolated from Echinaceaspecies, or with 
corresponding ethanol vehicle, in the absence or presence of phytohemagglutinin and phorbal 
ester. E. purpurea extracted in a solvent mixture of 95:5 ethanol/water dose-dependently 
inhibited IL-2 production. This IL-2 inhibitory activity correlated with the presence of 
alkylamides but not caffeic acid derivatives, as determined by high performance liquid 
chromatography/electrospray ionization-mass spectrometry analysis. Simultaneous measurement 
of secreted IL-2 by ELISA and cell viability by the XTT assay showed that the 95:5 
ethanol/water extract of E. purpurea was both IL-2 suppressive and cytotoxic at 50 and 
100 μg/mL. Lower concentrations from 6.25 to 25 μg/mL significantly decreased IL-2 
production but not cell viability. Alkylamides at concentrations found in a 50 μg/mL extract 
decreased IL-2 production by approximately 50%. Two Echinacea-derived alkylamides 
significantly depressed IL-2 production but not cell viability in a dose-dependent manner. Thus, 
alkylamides present in E. purpurea suppress the ability of activated Jurkat T cells to produce IL-
2 independently of direct, cytotoxic effects. 
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1. Introduction 
Perennial plants in the genus Echinacea have been traditionally used by Native Americans to 
treat cold and flu symptoms, reduce inflammation and heal wounds [1]. One of the main 
constituent groups present in ethanol/water extracts of Echinacea with reported bioactivity is the 
alkylamides. Reported activities ofEchinacea alkylamides include both anti-inflammatory and 
macrophage modulatory effects. Dose-dependent inhibition of 5-lipoxygenase by an alkylamide 
fraction of Echinacea purpurea roots (92.5% at 50 μM) has been reported [2]. 
Specific Echinacea alkylamides have since been identified that inhibit both 5-lipoxygenase and 
cyclooxygenase, upstream enzymes involved in the production of leukotrienes and 
prostaglandins [3] and [4]. Evidence that alkylamides from Echinacea induce tumor necrosis factor 
α (TNF-α) mRNA but not protein in LPS-treated primary human monocyte/macrophages has 
been reported in vitro[5], as has their inhibition of LPS-induced NO production in human 
macrophages [6]. In vivo, 4-day oral administration of 12 μg/kg/day E. purpurea alkylamides 
significantly enhanced phagocytic activity of alveolar macrophages in mice [7]. Caffeic acid 
derivatives also present in Echinacea extracts are reported to have direct antiviral 
activity [8] and [9]. These data suggest that alkylamides have the dual actions of anti-inflammatory 
and indirect antiviral effects, which together may influence the course of upper respiratory 
infection (URI) [10]. However, no data on the effects of alkylamides on measures of T cell-
specific immunity, known to play a key role in cell mediated immune responses to 
URI [11] and [12] have been reported. 
Few studies report the modulation of T cell activation markers, such as IL-2, by Echinacea. IL-2 
is a critical autocrine growth factor upregulated upon T cell activation that is required for the 
clonal expansion of T cells[13]. IL-2 is also an important cytokine involved in regulatory T cell 
activation and expansion [14]. The production of IL-2 has been linked to decrease in symptoms 
and reduction of virus recovery in experimental rhinovirus infection [15]. Thus, modulatory 
effects on IL-2 protein production may influence T cell specific immune responses to infection. 
In vivo, 4 weeks of oral administration of Echinacea aerial parts increased serum IL-2 levels 
320-fold in rats [16]. In vitro, IL-2 mRNA production was decreased over a 24-h period in human 
peripheral blood leukocytes treated with an E. purpurea fresh plant extract [5]. Neither of these 
studies assessed the effects of Echinacea on IL-2 induction by activated T cells. Thus, the effects 
ofEchinacea and alkylamides on T cell activation-induced IL-2 production are unknown. To test 
the hypothesis that Echinacea extracts modulate mitogen-induced IL-2 secretion, we assessed the 
effects of four aerial E. purpurea extracts and two classes of reportedly bioactive constituents, 
alkylamides and caffeic acid derivatives, on IL-2 production and cell viability upon PHA/PMA 
stimulation of Jurkat E6.1 T cells. 
2. Material and methods 
2.1. Echinacea extracts 
Extracts were prepared at HerbPharm, Inc. (Williams, OR) from 2-year-old cultivated E. 
purpurea leaves and flowers by drying at 80 °C for 8 days and macerating for 7 days at a starting 
ratio of 1:5 (w/v) in four different ethanol/water menstruums (95:5, 75:25, 50:50, and 25:75). A 
voucher specimen was independently species verified (Steven Foster Group, Inc., Fayetteville, 
Arkansas). Undiluted extracts tested negative for microbial contamination by triple sugar iron 
plate inoculation. Extracts tested negative for endotoxin contamination by the Limulus 
Amebocyte Lysate (LAL) gel assay (Cambrex Corp., East Rutherford, NJ) at the limit of 
detection (< 0.125 EU/mL). For testing, dry plant masses were measured after lyophilization, and 
mg dry plant material per mL diluent determined. E. purpurea extracts were diluted to 0.1 to 
100 μg dry plant material/mL final concentration for assay of IL-2 production alone, and diluted 
to 1.25 to 100 μg/mL for the IL-2 production/cell viability experiments, with ethanol adjusted to 
0.5% final concentration. 
2.2. Echinacea reference standards 
Reference standards of Echinacea spp. (ChromaDex, Inc., Santa Ana, CA), known to be present 
in E. purpurea extracts, included: 
Alkylamides: 
1) Dodeca-2(E),4(E),8(Z),10(Z)-tetraenoic acid isobutylamide; 
2) Dodeca-2(E),4(E)-dienoic acid isobutylamide 
Caffeic acid derivatives: (1) Caftaric acid; (2) Cichoric acid; (3) Chlorogenic acid 
Alkylamides and cichoric acid were reconstituted in 95% ethanol, and caftaric acid and 
chlorogenic acid in 47.5% ethanol (in distilled water) to prepare 5 mg/mL stock solutions. 
Reconstituted stock solutions were diluted to 0.625–25 μg/mL final concentration for assay. The 
25-μg/mL standard solutions tested negative for endotoxin contamination at the limit of detection 
(< 0.125 EU/mL). 
2.3. Mitogenic stimulation 
Optimal stimulant conditions and incubation time to elicit sub-maximal IL-2 production by 
Jurkat cells were determined using phytohemagglutinin (PHA, Sigma-Aldrich, Milwaukee, WI) 
and phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich). Jurkat cells (1 × 106 cells in 1 mL) 
were treated with 5 μg/mL PHA; 10 ng/mL PMA; or 1 μg/mL PHA + 1 ng/mL PMA and 
incubated at 37 °C, 5% CO2, and 95% relative humidity. Supernatants were harvested after 4, 12, 
and 24 h and stored at − 80 °C until IL-2 ELISA (IL-2 DuoSet, R&D Systems Minneapolis, 
MN). Optimal conditions for sub-maximal IL-2 production in the IL-2 production/cell viability 
assay were determined by titrating PHA concentrations at a fixed PMA concentration (1 ng/mL) 
at four different cell concentrations from 5 × 103–4 × 104 cells/mL. Secreted IL-2 concentration 
vs. PHA concentration was plotted and IL-2 concentration determined by the association curve 
produced using LABfit® Curve Fitting Software v.7.2.33 [17]. 
2.4. Cell culture followed by ELISA 
Jurkat E6.1 cells (ATCC, Manassas, VA) were cultured in RPMI 1640 containing phenol red, 
25 mM HEPES, 1 mM sodium pyruvate, 2 mM l-glutamine and 10% fetal bovine serum (Life 
Technologies, Inc., Rockville, MD) and plated at 1 × 106 cells in 1 mL final volume. Cells were 
either untreated or treated with E. purpurea extracts (0, 0.1, 1, 10, 50, and 100 μg/mL in 0.5% 
ethanol final concentration) and either unstimulated or stimulated with PHA (2.5 or 5 μg/mL) 
and PMA (1 ng/mL). Supernatants from single wells per test condition were collected at 24 h and 
stored at − 80 °C until IL-2 ELISA. IL-2 levels of triplicate samples were determined by 
subtracting background absorbance at 550 nm (OD550) from absorbance at 450 nm (OD450) using 
a microplate reader (FL-600, Bio-Tek, Inc., Woburn, MA) and extrapolation from IL-2 standard 
curves using accompanying KC4 software (Bio-Tek, Inc., Woburn, MA). 
2.5. Simultaneous IL-2 production/cell viability assay 
An assay was developed to measure cell viability and IL-2 concentration of supernatants from 
the same wells following treatments. Medium as described in Section 2.4 but without phenol red 
was used. Triplicate cultures for each test condition served as three independent measurements of 
IL-2 production and cell viability. Jurkat cells were plated in 96-well plates at 2 × 104 cells/well 
in 200 μL. For the cell viability standard curve, cells plated in triplicate wells at 2.5 × 104; 
2 × 104; 1.5 × 104; 7.5 × 103; 5.0 × 103; 2.5 × 103; and 0 cells/well (in 250 μL) were 
unstimulated. Test samples (25 μL E. purpurea (95:5 ethanol/water), 0.5% ethanol vehicle 
control, or standard isolates) and 25 μL stimuli (6 μg/mL PHA + 1 ng/mL PMA final 
concentration) were added. After 24 h at 37 °C, 5% CO2, 95% relative humidity, supernatant 
(100 μL) was removed without disturbing cells and tested for IL-2 using ELISA. 
For the XTT/PMS assay to assess cell viability [18], 100 μL of supernatant was removed from cell 
standard wells, and 100 μL of 1 mg/mL 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT, Sigma-Aldrich) plus 0.02 mM phenazine methosulfate (PMS, 
Sigma-Aldrich) in medium added. After 5 h at 37 °C, 5% CO2 and 95% humidity, OD450–
OD650 was measured and a cell concentration standard curve generated, from which viable cell 
numbers of the test wells were extrapolated. The caffeic acid derivatives reacted with XTT/PMS, 
adding color that interfered with absorbance readings. Interference was compensated for by 
creating no cell control wells of the XTT/PMS reagent and caffeic acid derivatives at each test 
concentration, and subtracting calculated cell number of corresponding control well from sample 
cell number. 
2.6. Analysis of caffeic acid derivatives and alkylamides with HPLC/ESI-MS 
The caffeic acid derivatives and alkylamides in the E. purpurea extracts were analyzed using 
high performance liquid chromatography/electrospray ionization-mass spectrometry (HPLC/ESI-
MS). For each sample, an aliquot (1 mL) of E. purpurea extract was centrifuged at 200×g to 
remove particulate matter and filtered with a 0.2-μm nylon filter. A binary pump HPLC 
(HP1100, Agilent, Palo Alto, CA) with a C18 column (Alltech, 50 × 2.1 mm, 3.0 μM particle 
size) was used, and duplicate injections of 10 μL performed. The gradients employed were 
(A = 1% acetic acid in nanopure water and B = HPLC grade acetonitrile): 
1) Caffeic acid derivatives: t = 0 to 4 min, 90% A; t = 4 to 15 min, 90% A to 60% 
A; t = 15.1 to 19 min, 0% A; t = 19.1 to 24 min, 90% A. 
2) Alkylamides: t = 0 to 4 min, 50% A; t = 4 to 11 min, 50% A to 23% A; t = 11.1 min to 
16 min, 0% A;t = 16.1 to 19 min, 50% A. 
The HPLC was interfaced to an ion trap mass spectrometer with an electrospray ionization 
source (LCQ Advantage, Thermo Finnigan, San Jose, CA) for detection. Caffeic acid derivatives 
were analyzed in the negative ion mode and alkylamides in the positive ion mode. The scan 
range was 150 to 1500 m/z, capillary temperature was 275 °C, and spray, capillary, and tube lens 
voltages were 4.5 kV, 10 V, and 50 V, respectively. 
Constituents in the extracts were identified according to their molecular weights, HPLC retention 
times, and MS–MS fragmentation patterns using a previously published method [19]. 
Quantification was accomplished as described [19]. Standards (Chromadex, Santa Ana, CA) were 
used to quantify caffeic acid derivatives, and alkylamide concentrations were estimated based on 
a calibration curve for undeca-2Z,4E-diene-8,10-diyonic acid isobutylamide, which was isolated 
from an E. purpurea extract. 
2.7. Statistical calculations 
Data were subjected to one-way ANOVA using SPSS 13.0 (SPSS Inc., Chicago, IL) with each 
extract or constituent as a factor and each concentration as a different treatment. The treatment 
means (N = 3) were compared to vehicle control using Tukey's Honestly Significant Different 
(HSD) post hoc analysis (two-tail, alpha level 0.01). 
3. Results 
3.1. PHA titration to determine submaximal IL-2 production 
Jurkat cell stimulants were selected based on earlier published studies [20] and confirmatory 
experiments. PHA or PMA alone did not stimulate IL-2 production over 24 h, but the 
combination did. The optimal mitogenic stimulation conditions for sub-maximal IL-2 production 
in the IL-2 production/cell viability assay were determined in PHA titration experiments, with 
PMA held constant at 1 ng/mL. For 2 × 104 cells/well, the PHA concentration yielding 
approximately half maximal IL-2 concentration (714 pg/mL) was calculated to be 6 μg/mL PHA 
(Fig. 1). A confirmatory ELISA of the same supernatant showed 654 ± 50 pg/mL IL-2 induced 
by 6 μg/mL PHA and 1 ng/mL PMA, verifying these conditions as appropriate for the IL-2 
production/cell viability assay. 
 
Fig. 1. IL-2 response of Jurkat T cells to increasing PHA and fixed PMA concentrations. PHA 
concentrations were tested at 1/2 log dilutions from 0.1 to 100 μg/mL. The association curve was 
extrapolated by specifying the maximum of 4-point parameters with the lowest chi-square value 
for the best fit. Maximum IL-2 at 24 h was calculated to be 1032.9 pg/mL at the PHA 
concentration of 19.2 μg/mL and 714.7 pg/mL at 6 μg/mL PHA, with cell concentration at 
2 × 104 cells/well. 
3.2. E. purpurea extracts suppressed IL-2 production 
Echinacea treatment alone did not stimulate IL-2 production (data not shown). The effect of 
treatment with four distinct E. purpurea extracts (95:5, 75:25, 50:50, or 25:75 ethanol/water 
menstruums) on IL-2 production upon PHA/PMA-stimulation of Jurkat cells was determined 
( Fig. 2). Mean percent IL-2 production relative to the stimuli alone condition and standard 
deviations from three independent experiments are shown. E. purpurea extracted in 95:5 
ethanol/water suppressed IL-2 production by approximately 65% at 50 μg/mL, compared to 
0.5% ethanol vehicle-treated cells. This IL-2 suppressive effect was statistically significant 
(p < 0.0001) at 50 and 100 μg plant material/mL. 
 
Fig. 2.  IL-2 response of PHA/PMA stimulated Jurkat T cells to E. purpurea extracts. PHA/PMA 
stimulated Jurkat T cells were incubated with stimuli alone, vehicle (0.5% ethanol), or increasing 
concentrations of extracts, prepared from four distinct solvent mixtures: 95:5; 75:25; 50:50; and 
25:75 (ethanol/water). For each treatment condition, the ratio of measured IL-2 level was divided 
by the mean of stimuli alone control. Error bars represent the variability of three independent 
assays. Final ethanol concentration of each extract on cells was adjusted to 0.5%. The treatment 
means (N = 3) were compared to vehicle control using Tukey's Honestly Significant Difference 
(HSD) post hoc analysis (two-tail, alpha level 0.01). 
3.3. Alkylamides and caffeic acid derivative content varied in distinct E. purpurea extracts 
The alkylamides and caffeic acid derivatives detected in E. purpurea extracts are known 
constituents of this plant, and their structures have been published elsewhere [21]. The most 
abundant alkylamides were dodeca-2(E),4(E),8(Z),10(E/Z) tetraenoic acid isobutylamide and 
undeca-2(Z),4(E)-diene-8,10-diynoic acid isobutylamide. Table 1 indicates the amount of each 
compound found in the original, undiluted E. purpureaextracts. Alkylamides were extracted at 
the highest level by 95:5 ethanol/water (964 μg/mL), while no alkylamides were present in the 
25:75 ethanol/water extract. In contrast, the highest amount of cichoric acid (1030 μg/mL) was 
found in the 50:50 extract, with much less in the 95:5 extract (13 μg/mL). 
Table 1. Constituent concentrations in original E. purpurea extracts 
E. 
purpurea constitu
ent 
95:5a(26.7 mg/
mL) 
75:25a(85.3 mg/
mL) 
50:50a(93.0 mg/
mL) 
25:75a(95.3 mg/
mL) 
 Concentration ± absolute standard deviation in μg/mL 
Undeca-diene-
diynoic acid 
isobutylamide 
24 ± 1 6 ± 1 4 ± 1 0 ± 0 
Dodeca-
tetraenoic acid 
isobutylamide 
940 ± 30 720 ± 20 215 ± 6 0 ± 0 
Caftaric acid 8 ± 1 112 ± 2 461 ± 5 422 ± 5 
Cichoric acid 13 ± 7 580 ± 20 1030 ± 40 660 ± 20 
Chlorogenic acid 4 ± 6 19 ± 6 12 ± 6 4 ± 5 
Total alkylamides 964 ± 30 726 ± 20 219 ± 6 0 ± 0 
Total caffeic acid 
derivatives 
25 ± 9 711 ± 20 1503 ± 40 1086 ± 30 
Undiluted E. purpurea extracts prepared with solvents of different ethanol/water ratios were 
analyzed by HPLC/ESI-MS. Caffeic acid derivatives (caftaric, cichoric, chlorogenic acid) and 
alkylamides were eluted by different HPLC water/acetonitrile gradients. Quantification of caffeic 
acid derivatives was performed using commercially available standards and alkylamides were 
quantified using an isobutylamide isolated from an E. purpurea extract. The constituent profiles 
differed considerably depending on the ethanol content used in the extraction solvent.    
aEthanol/water ratio of solvent mixtures used to prepare each E. purpurea extract. 
Concentrations in parentheses indicate dry plant material/mL solvent. 
Because the 95:5 ethanol/water E. purpurea extract exerted a significant IL-2 inhibitory effect at 
50 μg plant material/mL ( Fig. 2), the concentrations of total alkylamides and caffeic acid 
derivatives in each E. purpureaextract at this concentration were calculated ( Fig. 3) based on 
quantities of these constituents in the undiluted extracts. Concentrations of caftaric acid, cichoric 
acid, and chlorogenic acid in the 50 μg/mL 95:5 ethanol/water extract were 15.0, 24.4, and 
7.5 ng/mL, respectively, totaling 0.05 μg/mL caffeic acid derivatives. Concentrations of the 
alkylamides undeca-2(Z),4(E)-diene-8,10-diynoic acid isobutylamide and dodea-
2(E),4(E),8(Z),10(E/Z) tetraenoic acid isobutylamide were 0.05 and 1.76 μg/mL, respectively, 
giving a total of 1.81 μg/mL alkylamides in this extract. Total alkylamide concentration in the 
75:25 ethanol/water extract was 0.42 μg/mL. The total caffeic acid derivative content was 
highest in the 50:50 ethanol/water extract (0.81 μg/mL). 
 
Fig. 3. Total alkylamide and caffeic acid derivative concentrations in E. purpurea extracts at 
50 μg plant material/mL dilution. Concentrations were calculated based on the data obtained 
from quantities of constituents present in undiluted extracts as determined by HPLC/ESI-MS. 
3.4. Echinacea alkylamides suppressed IL-2 production 
We devised the simultaneous IL-2 production/cell viability assay to measure percent change in 
IL-2 production and cell viability relative to vehicle control following PHA/PMA stimulation of 
Jurkat T cells with or without E. purpurea extracts or chemical constituents thereof ( Fig. 4a–f). 
The 95:5 ethanol/water E. purpurea extract dose-dependently suppressed IL-2 ( Fig. 4a). At 
dilutions of 50 and 100 μg plant material/mL, this extract was also cytotoxic to the cells; the 
decreases in both IL-2 production and cell viability at these extract concentrations were 
statistically significant compared to vehicle control. However, at concentrations between 6.25 
and 25 μg/mL, a statistically significant difference was observed in the IL-2 suppressive effect of 
this extract compared to vehicle (p < 0.003), but not in change in cell viability (p > 0.219). 
 
Fig. 4. Percent changes of IL-2 production and viable cell number relative to stimuli alone 
control. Cells were stimulated by PHA/PMA in the presence of vehicle or increasing 
concentrations of Echinacea 95:5 ethanol/water extract (a), or standard isolates (b–f). Percent 
change in IL-2 production or viable cell number relative to stimuli alone control is shown. 
Vehicle control is shown as 0 μg/mL. One-way ANOVA was performed on IL-2 change or 
viable cell number change with 95:5 extract or each constituent as a factor and each 
concentration as a different treatment. The treatment means (N = 3 independent wells) were 
compared to vehicle control using Tukey's Honestly Significant Difference (HSD) post hoc 
analysis (two-tail, alpha level 0.01). 
The effects of two standards of alkylamides, compounds which were present in the E. 
purpurea extracts with high ethanol content, were evaluated. Cells were treated with dodeca-
2(E),4(E),8(Z),10(Z)-tetraenoic acid isobutylamide ( Fig. 4b) or dodeca-2(E),4(E)-dienoic acid 
isobutylamide ( Fig. 4c) at 0.625 to 25 μg/mL, which bracketed the concentration range of 
alkylamides present in the E. purpurea extract at test concentrations on cells. Both alkylamides 
showed a consistent and statistically significant dose-dependent IL-2 suppressive effect 
compared to vehicle (p < 0.001), while the slight changes in cell viability induced by these 
agents compared to the vehicle control were neither consistent nor statistically significant 
(p > 0.08). 
3.5. Echinacea caffeic acid derivatives did not suppress IL-2 production 
The effects of caffeic acid derivatives at concentrations relevant to the extract concentration were 
also evaluated. No caffeic acid derivative significantly altered IL-2 production at any 
concentration evaluated (Fig. 4d–f). However, the Tukey's HSD test showed a statistically 
significant decrease in cell viability caused by chlorogenic acid at the 0.625 μg/mL concentration 
(p < 0.008) ( Fig. 4e). Cichoric acid showed a statistically significant proliferative effect on 
Jurkat cells at 2.5 (p < 0.004) and 10 μg/mL (p < 0.006) ( Fig. 4f). 
4. Discussion 
Alkylamides were found at highest concentration in aerial 95:5 ethanol/water E. 
purpurea preparations, and correlated with dose-dependent inhibition of IL-2 production by 
PHA/PMA-stimulated Jurkat T cells. This is the first report of an inhibitory effect 
of Echinacea alkylamides on production of IL-2, an important factor involved in expansion of 
clonal T cell populations in response to infection. By simultaneous assay of IL-2 production and 
cell viability, Echinacea alkylamide isolates were shown to significantly inhibit IL-2 but not cell 
viability. Studies to determine if the reported suppression is specific to IL-2 or whether 
alkylamides are more generally inhibiting to cytokine secretion are ongoing. One site of action of 
alkylamides has been identified as the cannabinoid 2 receptor (CB2) on 
monocytes/macrophages [5]. Jurkat T cells express CB2[22], so experiments to determine if the IL-
2 suppressive effect is dependent on alkylamide binding to the CB2 receptor are warranted. 
Determination of the mechanism of alkylamide-induced IL-2 suppression is expected to 
contribute to the identification of appropriate and effective uses of Echinacea. 
The physiological relevance of these results depends on a number of factors, including 
alkylamide pharmacokinetics and combination effects of different alkylamides and other 
constituents. Alkylamides do appear to be capable of reaching T cells in vivo. Alkylamides were 
detected in human serum at 17.4 ng/mL only 30 min after a single oral dose of E. 
angustifolia tincture [23]; at 44 ng/mL after 1 h of a single dose of E. purpurea tincture [24]; and at 
336 ± 131 ng/mL within 20 min after ingestion of an ethanolic extract of E. purpurea and E. 
angustifolia in tablet form [25]. The concentrations found in this last study are only two- to four-
fold lower than the IL-2 suppressive alkylamide concentrations in this study. Thus, the 
hypothesis that alkylamide-induced IL-2 suppression modulates immune responsiveness in vivo 
warrants future testing. 
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